Cypher Edges Out Taxus In A Meta-Analysis Of Six Head-To-Head Trials
This article was originally published in The Gray Sheet
Executive Summary
A meta-analysis of six drug-eluting stent trials suggests that sirolimus-elutings stents are associated with a lower risk of restenosis and target vessel revascularization than paclitaxel-eluting stents
You may also be interested in...
REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association
REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association
Boston Scientific Redraws U.S. Sales Map, Adds 25% More Taxus Reps
Boston Scientific plans to halt the decline of its U.S. drug-eluting stent market share by expanding its domestic interventional cardiology sales force by about 25% in the third quarter